Drug Landscape ›
mRNA COVID-19 ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 9
Most-reported reactions
Varicella Zoster Virus Infection — 2 reports (22.22%) Acute Kidney Injury — 1 report (11.11%) Altered State Of Consciousness — 1 report (11.11%) Bradycardia — 1 report (11.11%) Drug Ineffective — 1 report (11.11%) Gait Disturbance — 1 report (11.11%) Therapy Non-Responder — 1 report (11.11%) Uraemic Encephalopathy — 1 report (11.11%)
Source database →
mRNA COVID-19 in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is mRNA COVID-19 approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for mRNA COVID-19 in United States?
Duke University is the originator. The local marketing authorisation holder may differ — check the official source linked above.